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Abstract
Cross-sectional studies in dialysis demonstrate muscle wasting associated with loss of function, increased morbidity and
mortality. The relative drivers are poorly understood. There is a paucity of data regarding interval change in muscle in pre-
dialysis and dialysis-dependant patients. This study aimed to examine muscle and fat mass change and elucidate
associations with muscle wasting in advanced CKD. 134 patients were studied (60 HD, 28 PD, 46 CKD 4–5) and followed up
for two years. Groups were similar in age, sex and diabetes prevalence. Soft tissue cross-sectional area (CSA) was measured
annually on 3 occasions by a standardised multi-slice CT thigh. Potential determinants of muscle and fat CSA were assessed.
Functional ability was assessed by sit-to-stand testing. 88 patients completed follow-up (40 HD, 16 PD, 32 CKD). There was
a significant difference in percentage change in muscle CSA (MCSA) over year 1, dependant on treatment modality
(x2 = 6.46; p = 0.039). Muscle loss was most pronounced in pre-dialysis patients. Muscle loss during year 1 was partially
reversed in year 2 in 39%. Incident dialysis patients significantly lost MCSA during the year which they commenced dialysis,
but not the subsequent year. Baseline MCSA, change in MCSA during year 1 and dialysis modality predicted year 2 change
in MCSA (adjusted R2 = 0.77, p,0.001). There was no correlation between muscle or fat CSA change and any other factors.
MCSA correlated with functional testing, although MCSA change correlated poorly with change in functional ability. These
data demonstrate marked variability in MCSA over 2 years. Loss of MCSA in both pre-dialysis and established dialysis
patients is reversible. Factors previously cross-sectionally shown to correlate with MCSA did not correlate with wasting
progression. The higher rate of muscle loss in undialysed CKD patients, and its reversal after dialysis commencement,
suggests that conventional indicators may not result in optimal timing of dialysis initiation.
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Introduction
Significant muscle atrophy [1,2] and associated weakness [3] is
seen in both dialysis patients and in patients with chronic kidney
disease (CKD) stages 3–4. This is associated with increased
morbidity and mortality [4,5].
There are many associations already reported as being
associated on a cross sectional study basis with muscle wasting.
These include decreasing glomerular filtration rate (GFR) [6],
dialysis [7], age [8] and diabetes [9,10]. Other key drivers of
muscle mass in CKD include exercise, acidosis and insulin
resistance [11,12] as well as inflammation [12]. Muscle atrophy
can be assessed via various methods, and previous work in our
group has shown good correlation between muscle cross-sectional
area and functional performance, serum albumin, age and
inflammatory status in CKD stages 4–5, haemodialysis (HD) and
peritoneal dialysis (PD) [13]. More recently, reduced muscle and
fat mass evidenced by anthropomorphic assessment (mid-arm
circumference, triceps skinfold) appears able to predict mortality in
haemodialysis populations [14,15].
These changes have previously been attributed to inadequate
dietary protein intake, but recent advances in our understanding of
this area indicate other processes are involved. Animal models
have suggested that the ubiquitin-proteasome system, the protease
caspase-3 [16] and suppression of phosphatidylinositol 3-kinase
(PI3-K) activity [17] may be responsible for accelerated muscle
breakdown in CKD. Recent work has increased the focus on these
key pathways in humans [11,12,18]. The triggers are unclear,
although IGF-1 is implicated. Insulin resistance is common and is
associated with muscle wasting in non-diabetic dialysis patients
[19,20,21]. Muscle turnover increases during HD, resulting in net
increase in catabolism [22]. Finally, electromyography (EMG)
studies have suggested that circulating uraemic toxins depress
muscle function, and this improves acutely with haemodialysis
[23].
Muscle mass can be modulated by exercise training
[7,24,25,26,27], which improves both muscle structure and
function in dialysis patients. Also, anabolic steroids increase thigh
muscle cross-sectional area in an additive manner to resistance
exercise training in this group [28]. Finally, L-carnitine supple-
mentation may be effective in some dialysis patients [29].
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There is significantly less literature concerning the role of fat.
Fat mass in haemodialysis patients correlates with increasing age
[8] and diabetic haemodialysis patients have more thigh adipose
tissue than non-diabetics [7]. In haemodialysis patients, low
baseline body fat percentage and fat loss over time are
independently associated with higher mortality [30]. Much of
the available data regarding body fat in CKD has been generated
as part of work on the malnutrition-inflammation-atherosclerosis
(MIA) complex, as the contribution of adipose tissue to inflam-
mation via adipokine (including leptin and adiponectin) and
cytokine (including TNFa and IL-6) secretion [31] is becoming
further understood.
Methods
Objectives
The aim of this study was to examine the interval muscle and fat
change, predictors of such change, and associated functional
abnormalities in a cohort of pre-dialysis CKD, HD and PD
patients.
Participants
We studied 134 subjects (46 CKD stage 4, 60 HD, 28 PD)
recruited from Derby City General Hospital [13]. Exclusion
criteria were previous transplantation, limb amputation or
conditions likely to increase muscle catabolism including active
sepsis or malignancy. All prevalent patients were approached (291
patients in May 2003, at the start of recruitment). CKD stage 4
patients were defined by a minimum of two eGFR (MDRD)
measurements of 15–30 ml/min. Dialysis modality was subject to
patient choice, no patient had switched modality during the study.
All dialysis patients were established for at least 6 months.
PD patients were all treated with bicarbonate/lactate buffered
fluid (PhysionealH, Baxter, UK). 9 patients used automated PD, 19
patients used continuous ambulatory PD (3–5 exchanges/day).
HD patients received three sessions of at least 4 hours per week.
Hospal Integra (Mirandola, Italy) monitors and low-flux poly-
sulphone dialysers (1.5–2.0 m2, LOPS 15–20H, Braun Medical
Ltd, Sheffield, UK). Dialysate containing 1.25 mEq/l calcium and
134 mmol/l sodium was used in all sessions. All sessions utilised
bicarbonate-based HD.
Standard dietary advice and support was provided to all subjects
as standard policy. Daily sodium intake was limited to 100 mmol,
and daily protein to 1.2 g/kg for at least 1 year prior to study.
Description of Procedures and Investigations
Participants were studied at baseline, 12 months and 24 months
(Figure 1).
Data collection
Age, gender, comorbiditity, medication, height, weight and
tobacco and alcohol use were recorded for all patients. Biochem-
ical parameters (haemoglobin, serum phosphate, serum corrected
calcium, albumin (bromocresol purple method) and serum
bicarbonate) were time-averaged over the previous 6 months.
High sensitivity CRP was assayed at each investigatory visit by
ELISA (DRG Diagnostics, Marburg, Germany). The most recent
(less than one month before each visit) dialysis adequacy was
recorded.
Imaging
Muscle and fat CSA was assessed by computed tomography
utilising a GE Medical Systems LightSpeed16 multi-slice spiral
scanner. Non-contrast enhanced images were obtained from
supine subjects. A standardised 6 cm section of thigh was scanned,
20 cm above the tibial plateau, in 2.5 mm slices without overlap.
Total radiation exposure was calculated to be 116 mgy, lower than
a standard chest X-ray (120 mgy).
Scans were independently scored by two investigators, blinded
to patient group and identity, using GE Medical Systems
Advantage Workstation software (intra-observer CoV of ,1%)..
Muscle and fat CSA was measured by drawing an appropriate
region of interest around the images with windowing for the
appropriate density (fat and non-contractile connective tissue -200-
0 Hounsfield units (HU), muscle 0-200 HU). The mean of the top,
middle and bottom images was taken, and then adjusted for
patient height [13]. This technique aimed to create a comparable
and repeatable assessment between patients allowing for differing
patient morphology.
Functional muscle assessment
Physical function was assessed using sit-to-stand (STS) testing.
Subjects were timed rising from sitting in a chair of standard
height (46 cm) and returning to sitting. This was demonstrated
prior to assessment. Both muscle power (STS 5 – time to perform
5 iterations) and endurance (STS 60 – maximum iterations in
60 seconds) were assessed. This type of assessment has been
validated against more detailed techniques [32,33], may predict
outcome [34], and has been used in the study of CKD patients
[13,35,36].
Ethics
Appropriate ethical approval was granted by the South
Derbyshire Local Research Ethics Committee and all patients
provided written informed consent.
Statistical methods
Group data are presented as mean 6 SD unless otherwise
stated. All data were tested for normality. Analysis was performed
using SPSS v12.0.1 (SPSS Inc, Chicago, IL). Categorical data was
compared using Chi-square test, continuous data using paired or
unpaired Students t-test or one-way ANOVA with Tukey’s
correction as appropriate. Significant alteration in muscle CSA
and function (STS-60 and STS-5) was defined as a 5% change.
Results
Demographics
88 patients completed 2 year follow up (32 CKD, 40 HD and 16
PD). Their baseline demographics are presented in Table 1.
Causes of patient non-completion (46) were primarily death (21),
as well as study withdrawal (11) and non-attendance for all 3
Figure 1. Study diagram.
doi:10.1371/journal.pone.0065372.g001
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annual CT scans (14). Baseline muscle CSA (MCSA) was not
significantly different in those who died (1015662724 vs
1032862582 mm2; p = 0.8), nor did change in muscle mass
during the first 12 months predict death during the second year.
Muscle cross-sectional area
There was significant difference in percentage change in MCSA
during year 1 dependant on baseline treatment modality
(x2 = 6.46; p = 0.039). More CKD patients lost muscle mass
(47%) than PD (25%) or HD (35%).
MCSA change during year 1 was not predictive of change
during year 2 (Table 2). Whilst, as a group, MCSA decreased over
the study (24.368.0%; p,0.001), 7 patients gained MCSA and
over 50% (45 of 88) remained static. These observations were not
dependent on baseline modality (CKD 25.067.1; PD 24.368.4;
HD 23.868.6%).
15 CKD patients started dialysis during year 1 (10 HD, 5 PD).
There were few demographic or biochemical differences between
dialysis initiators and those remaining without renal replacement
therapy (Table 3). Incident dialysis patients overall lost MCSA
during the year which they commenced dialysis, but not in the
subsequent year (Year 1 24.466.0%, p= 0.01; Year 2
21.5610.1%, p= ns)(Tables 4 and 5). Change during year 1
and year 2 was weakly inversely correlated (R=20.52; p = 0.047).
Although there were no differences in year 1 MCSA change by
subsequent dialysis modality, recovery of MCSA in year 2 was
significantly more common among patients commencing HD (HD
367%; PD 210610%; p,0.01).
All demographics, baseline CT imaging, year 1 change in CT
imaging and year 1 bloods were examined as univariate predictors
Table 1. Baseline demographics for cohort.
CKD (32) PD (16) HD (40) Sig.
Age (years) 62612 63611 59615 ns
Male 17 (53%) 8 (50%) 27 (68%) ns
Diabetes mellitus 5 (16%) 4 (25%) 10 (25) ns
Smoking 4 (13%) 1 (6%) 5 (13%) ns
Dialysis vintage (months) - 33622 38625 ns
BMI (kg/m2) 2766 2563 2765 ns
Urea (mmol/l) 2368 2165 1964 0.02, 0.01**
eGFR (MDRD) (ml/min) 1665 - - n/a
Dialysis adequacy (Kt/V)a - 2.4460.52 1.2560.35 n/a
Previous CV morbidityb 8 (25%) 6 (38%) 7 (18%) ns
Total cholesterol (mmol/l) 5.260.9 4.661.0 4.461.0 0.002, ns*,***, 0.02**
HDL cholesterol (mmol/l) 1.460.3 1.460.3 1.360.3 ns
LDL cholesterol (mmol/l) 2.861.1 2.861.1 2.060.8 0.008, ns*,***, 0.012**
Triglycerides 1.961.2 2.260.8 2.461.8 ns
Serum phosphate (mmol/l) 1.4660.3 1.5860.2 1.7360.4 0.005, ns*,***, 0.03**
Serum corrected calcium (mmol/l) 2.4060.1 2.5460.1 2.4760.1 0.001, 0.01*, ns**,***
Calcium6Phosphate product (mmol2/l2) 3.5060.7 4.0160.7 4.2861.0 0.001, ns*,***, 0.001**
PTH (pg/ml) 1856103 3626333 3056318 ns
Albumin (g/l) 3463 2863 3463 ,0.001, ,0.001*,***, ns**
High-sensitivity C-reactive protein (mg/l) 4.1165.9 4.0264.7 8.24610 ns
Bicarbonate (mmol/l) 2364 2763 2363 ,0.001, 0.002*, ns**, 0.001***
Use of Vitamin D 10 (31%) 11 (69%) 22 (55%) 0.026
Lipid lowering therapy 11 (34%) 7 (44%) 13 (33%) ns
Use of non-Calcium containing binders 1 (3%) 10 (63%) 20 (50%) ,0.001
Use of Calcium containing binders 13 (41%) 6 (38%) 25 (63%) ns
Use of Calcium channel blockers 13 (41%) 5 (31%) 12 (30%) ns
Use of ACE inhibitors 15 (47%) 7 (44%) 6 (15%) 0.006
Use of Beta blockers 13 (41%) 2 (13%) 12 (30%) ns
Use of Epo 7 (22%) 13 (81%) 38 (95%) ,0.001
Results are mean 6 SD or number of observations (percentage) for categorical data.
Key/Notes :
ns – not significant.
*– comparison CKD vs PD.
**– comparison CKD vs HD.
***– comparison PD vs HD.
a– Kt/V is Weekly in PD, per session in HD.
b– defined as any previous description of ischaemic heart disease, heart failure, cerebrovascular disease or peripheral vascular disease.
doi:10.1371/journal.pone.0065372.t001
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of dialysis initiators change in MCSA in year 2. All identified
variables with a p-value less than 0.2 (Table 6) were then subjected
to a stepwise multivariable linear regression analysis. This
identified baseline MCSA, change in MCSA in year 1 and dialysis
modality as predictors of change in MCSA in Year 2 (adjusted
R2= 0.77; p,0.001) (Table 7).
There was no significant correlation between change in muscle
or fat CSA and other factors including age, gender, inflammatory
status, time-averaged bicarbonate, calcium, phosphate or change
in serum albumin.
Muscle function
MCSA correlated with both STS60 and STS5 at all assessments
(baseline R=0.45, p,0.001; R=20.45, p,0.001; 12 months
R= 0.55, p,0.001; R=20.50, p,0.001; 24 months R=0.47,
p,0.001; R=20.47, p,0.001). However, MCSA only contrib-
uted ,12% to the observed functional variability at baseline
Table 2. Change in MCSA, Year 1 vs. Year 2 for the entire
cohort.
Year 2
Lose No change Gain Total
Year 1 Lose 4 13 11 28
No change 19 28 4 51
Gain 5 4 0 9
Total 28 45 15 88
x2= 14.1; p,0.001.
doi:10.1371/journal.pone.0065372.t002
Table 3. Baseline demographics of Year 1 dialysis initiators (CKD cohort).
Remained non-RRT (17) Dialysis initiators (15) Sig.
Age (years) 63612 60612 ns
Male 9 (53%) 8 (53%) ns
Diabetes mellitus 2 (12%) 3 (20%) ns
Smoking 2 (12%) 2 (13%) ns
BMI (kg/m2) 2866 2666 ns
Urea (mmol/l) 2067 2868 0.004
eGFR (MDRD) (ml/min) 1964 1262 ,0.001
Previous CV morbidityb 3 (18%) 5 (33%) ns
Total cholesterol (mmol/l) 5.260.6 5.261.1 ns
HDL cholesterol (mmol/l) 1.360.3 1.560.4 0.038
LDL cholesterol (mmol/l) 2.861.2 2.861.1 ns
Triglycerides 2.261.3 1.661.1 ns
Serum phosphate (mmol/l) 1.3160.2 1.6460.2 ,0.001
Serum corrected calcium (mmol/l) 2.4160.1 2.3860.1 ns
Calcium6Phosphate product (mmol2/l2) 3.1460.5 3.9060.6 0.001
PTH (pg/ml) 1356130 1876143 0.026
Albumin (g/l) 3463 3463 ns
High-sensitivity C-reactive protein (mg/l) 3.4166.3 1.3263.5 ns
Bicarbonate (mmol/l) 2464 2263 ns
Use of Vitamin D 5 (29%) 4 (27%) ns
Lipid lowering therapy 4 (24%) 7 (47%) ns
Use of non-Calcium containing binders 1 (6%) 2 (13%) ns
Use of Calcium containing binders 3 (18%) 8 (53%) 0.027
Use of Calcium channel blockers 8 (47%) 5 (33%) ns
Use of ACE inhibitors 10 (59%) 5 (33%) ns
Use of Beta blockers 7 (41%) 6 (40%) ns
Use of Epo 2 (12%) 5 (33%) ns
doi:10.1371/journal.pone.0065372.t003
Table 4. Change in MCSA, Year 1 vs. Year 2 for CKD patients
who remained non-RRT.
Year 2
Lose No change Gain Total
Year 1 Lose 0 4 4 8
No change 4 2 1 7
Gain 0 2 0 2
Total 4 8 5 17
x2= 3.02; p = 0.082.
doi:10.1371/journal.pone.0065372.t004
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(STS60 Adj R2= 0.11, p= 0.003; STS5 Adj R2= 0.14, p,0.001).
In multi-variate modelling MCSA was displaced by age and
gender.
There was significant individual variability in the change in
both muscle power and endurance during year 1 and 2 (Tables 8
and 9). Change in MCSA correlated poorly with changes in
functional ability. STS60 and STS5 changes were dependent on
modality. Most variability observed in STS60 was in the CKD
(x2 = 10.3, p = 0.001), rather than dialysis groups (PD x2 = 0.7,
p = 0.779; HD x2 = 2.4; p= 0.122), and was not solely in those
commencing dialysis during the study. STS5 variability was also
more marked pre-dialysis, but was more consistent throughout the
cohort (CKD x2 = 3.0, p = 0.085; PD x2 = 2.8, p= 0.091; HD
x2 = 1.8, p = 0.176).
Although MCSA fell over the study, endurance improved
(STS60 +1669%; p= 0.001), despite no differences in anaemia
status.
Discussion
Whilst we [13] and others have previously documented cross-
sectional associations with muscle mass, prospective evaluation has
largely been only in intervention based studies. Such control
groups that existed in the small number of these studies that were
RCTs are limited in number and by the selection bias of the
patient demographic agreeing to take part in exercise based
studies. This therefore is the first report of the natural progression
of both muscle area and function in CKD. This cohort was
unselected, not exposed to any kind of exercise regime and
followed up for a sufficiently long period to constitute a valid
natural history study. Furthermore it is the first study to contain
prospective comparative data from well matched patients with non
dialysis requiring CKD, HD and PD.
The prevailing view has been that muscle wasting is an
inexorable consequence of CKD, and that once commenced,
progression is inevitable without intervention. Whilst this cohort
did lose muscle mass over the entire study period, the marked
variability between years 1 and 2 suggest that even without
intervention decline is not continuous. Furthermore, the significant
proportion who did not decline over the study affirms that muscle
wasting is not inevitable in CKD. During the time frame of this
study our patients were not routinely provided exercise advice.
Significant muscle wasting is known to occur in acute illness, thus
it is possible that the variability seen is in part related to episodic
catabolism not assessed in our study – the lack of association with
CRP reflecting assessment of baseline inflammatory status rather
than cumulative inflammatory load during the preceding year.
The role of acidosis is well documented in muscle wasting, yet we
did not demonstrate association with serum bicarbonate in this
study. We hypothesise that this reflects the low overall levels of
systemic acidosis in our cohort.
The increased prevalence of muscle wasting was seen in our pre-
dialysis cohort occurs despite all three (CKD, HD, PD) groups
being well matched for age, gender, diabetes prevalence, smoking
and body mass index (BMI). This observation is somewhat
counter-intuitive as CKD 4 patients are usually considered to be
less metabolically challenged than CKD 5 patients receiving
dialysis. Whilst our CKD 4 cohort were not characterised by a
delayed start of RRT (mean eGFR 18 ml/min), they were
however significantly more uraemic than the dialysis cohort. This
significant loss of muscle CSA in late stage CKD 4 suggests that
these patients are having increased disturbance of the catabolic/
anabolic balance, presumably as a result of advancing uraemia,
and that we are in danger of allowing them to loose ground in
these late stages by failing to appreciate this by biochemical
changes alone and failing to optimally time dialysis initiation. This
raises the possibility that we might be able to utilise this
acceleration of muscle wasting as an individualised biomarker of
metabolic decompensation, providing a rationale for when the
appropriate time to start dialysis might be. This would be
supported by our observations in dialysis initiators, in whom the
expected acceleration of muscle wasting when clinical deteriora-
tion of renal function resulted in the necessary commencement of
dialysis was not seen. It is likely that the observed improvement
relates to an improvement in the uraemic milieu with the
institution of renal replacement therapy, either via direct effects
on muscle structure and function, or secondary to improvement in
subjects’ activity promoting the rebuilding of muscle mass.
The differential effects of modality in the dialysis initiators are
challenging to explain. Indeed, some caution is required in
interpretation as this group is relatively small and not randomised.
However, dialysis modality was a free choice for participants and
there were no significant differences in age, gender or other
demographics, baseline renal function or inflammatory status.
Both insulin resistance [19,20] and plasma insulin concentration
[19] are associated with muscle breakdown in non-diabetics.
Diabetic dialysis patients demonstrate increased muscle break-
down c.f. non-diabetics [9,10]. Glucose-based PD therapy causes
hyperglycaemia and hyperinsulinaemia even in non-diabetics [37].
It is thus possible that these observed differences relate to the
deleterious effects of intraperitoneal glucose.
Our original findings of lower MCSA in dialysis patients [13]
are consistent with this study demonstrating pronounced muscle
loss pre-dialysis which is improved with dialysis. We hypothesise
that significant muscle loss is occurring in the final period before
renal replacement therapy is commenced, and whilst this is
improved with commencement of dialysis, patients do not return
to pre-existing ‘CKD’ levels. We did not see a relationship
Table 5. Change in MCSA, Year 1 vs. Year 2 for dialysis
initiators.
Year 2
Lose No change Gain Total
Year 1 Lose 1 3 3 7
No change 4 2 2 8
Gain 0 0 0 0
Total 5 5 5 15
x2= 1.5; p = 0.221.
doi:10.1371/journal.pone.0065372.t005
Table 6. Univariate associations in dialysis initiators for
change in MCSA during Year 2.
Variable R Sig.
Year 1 Modality 0.655 0.008
Diabetes 0.424 0.115
Year 1 Smoker 0.499 0.058
Year 1 Urea 20.522 0.046
Baseline MCSA 20.375 0.169
Year 1% change MCSA 20.520 0.047
doi:10.1371/journal.pone.0065372.t006
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between dialysis vintage and MCSA in our dialysis population in
this study, but do acknowledge that this may, in part, relate to the
inherent selection bias of the requirement of repeated assessments
in this study.
Whilst both endurance and power correlate with MCSA, this
represents only a relatively small contribution. There are thus
clearly other factors than muscle CSA affecting function, an
observation which is consistent with Kemp et al’s [2] findings of
lower MCSA, but normal contractile efficiency, in HD. Cheema
et al [27] showed no statistically significant change in muscle
CSA after exercise training, but a highly significant increase in
muscle function (both power and endurance), supporting this
observation that CSA is only a component of total functional
ability.
However, detailed further analysis of our cohort did not
demonstrate other consistent predictors of changes in function. It
is well documented that muscle structure affects function, and thus
it is a limitation of our study that muscle biopsies were not
performed. However, this study was designed to investigate the
relationship between muscle function and clinically relevant, readily
obtainable markers in common use.
Variability in MCSA could represent a lack of reproducibility
between scans. In part, this was the reason for the selection of 5%
as a cutoff for significant change, rather than a lower one. It would
not have been ethically appropriate to repeat CT assessment, and
it must be remembered that CT is a test in clinical use, with
reproducibility sufficient for clinical surveillance. Furthermore,
scan location was anatomically defined and care was taken during
analysis to ensure that the same area was being assessed on follow-
up scans. Cross-sectional CT has also been used in other studies of
muscle CSA [27,38]. However previous studies have relied on
single mid-thigh measurements, whilst we have taken the average
of 3.
Lack of relationship with age, gender, inflammatory status
or albumin is notable as there were significant differences with
these variables in our previous cross-sectional baseline report
of this cohort. It is thus likely that whilst they are associated
with current total muscle mass either changes in these factors
do not determine changes in muscle mass or they do so within
a time frame beyond the scope of this study. Cheema et al [27]
found a decrease in log CRP with exercise, but we did not
demonstrate any relationship between change in MCSA and
either cross-sectional or change in inflammatory status. This
was however a population defined by a relatively low
prevalence of systemic inflammation. This lack of significant
association between changes in these predictors and changes in
MCSA underlines that the pathophysiology involved is poorly
understood, and may suggest that the effect of the non-
modifiable factors (age, gender) coupled with the variability in
other factors (eg. exercise, dialysis modality, vascular change),
overwhelm these changes. Alternatively, the magnitude of
effect may simply leave our study underpowered to detect this.
Limitations
We acknowledge that we do not present data regarding protein
intake, insulin resistance or activity data. However, patients in our
unit were provided with routine dietetic advice as part of their
clinical care during this study, we did not recommend protein
restriction. Participants undertook normal activity levels during
the study.
We also acknowledge the number of participants who did not
complete the study. This reflects in part the high attrition rate of
CKD patients (accepting that generally a ‘fitter’ subgroup will
volunteer for clinical studies) combined with volunteers maintain-
ing the significant time commitment often needed to participate in
clinical research studies.
Table 7. Stepwise LR for dialysis initiators – dependent variable change in MCSA during year 2.
Unstandardized Coefficients
Standardized
Coefficients
B Std. Error Beta T Sig.
(Constant) 2.239 .105 22.281 .043
Dialysis Modality (HD) .131 .027 .633 4.878 .000
Year 1 change in MCSA (%) 2.989 .218 2.595 24.546 .001
Baseline MCSA (mm2) 21.540E-05 .000 2.322 22.445 .033
doi:10.1371/journal.pone.0065372.t007
Table 8. Change in STS60 function in year 1 and year 2.
Year 2
2 0 + Total
Year 1 2 1 1 11 13
0 1 1 4 6
+ 10 6 9 25
Total 12 8 24 44
(2 decrease, 0 no change, + increased).
x2= 7.7; p = 0.005.
doi:10.1371/journal.pone.0065372.t008
Table 9. Change in STS5 function in year 1 and year 2.
Year 2
2 0 + Total
Year 1 2 8 1 12 21
0 2 0 1 3
+ 13 4 2 19
Total 23 5 15 43
(2 decrease, 0 no change, + increased).
x2= 6.8; p = 0.009.
doi:10.1371/journal.pone.0065372.t009
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Conclusion
We have demonstrated variability in the natural course of
muscle wasting in CKD, most marked pre-dialysis with improve-
ment on dialysis. Change in muscle mass is not predicted by
factors associated cross-sectionally, and poorly predicts function.
Monitoring for accelerated muscle loss might represent an
attractive patient specific ‘bioassay’ for the need to commence
renal replacement therapy. This approach appears to warrant
further investigation.
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